Cue Biopharma (CUE) Short term Debt (2022 - 2025)

Cue Biopharma (CUE) posted Short term Debt of $689000.0 for Q4 2025, down 52.74% sequentially from $1.5 million in Q3 2025.

Cue Biopharma (CUE) Short term Debt (2022 - 2025) Analysis & Trends

Cue Biopharma has reported Short term Debt for 4 years, with the latest figure at $689000.0 in Q4 2025.

Quarterly Short term Debt changed N/A year-over-year to $689000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $689000.0 (changed N/A YoY) and the FY2025 annual result came in at $689000.0, changed N/A from the prior year.
Short term Debt slipped to $689000.0 in Q4 2025 per CUE's latest filing, from $1.5 million in the prior quarter.
Over five years, Short term Debt peaked at $4.0 million in Q2 2023 and troughed at $689000.0 in Q4 2025.
A 4-year average of $2.9 million and a median of $3.4 million in 2025 frame the typical range for Short term Debt.
The sharpest annual moves came in 2023 and 2025: Short term Debt soared 300.0% in 2023, then sank 63.55% in 2025.
Over 4 years, Short term Debt stood at $2.0 million in 2022, then soared by 101.88% to $4.0 million in 2023, then grew by 0.93% to $4.0 million in 2024, then tumbled by 82.78% to $689000.0 in 2025.
According to Business Quant data, Short term Debt over the past three periods registered $689000.0, $1.5 million, and $2.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Cue Biopharma	152.56 Mn	135.14 Mn	-

Download Data